Authors
Latest:
MRI/TRUS fusion-guided biopsy using UroNavPinto and colleagues provide an overview of MRI/TRUS fusion-guided transperineal biopsy utilizing the UroNav platform.
Latest:
MRI/TRUS fusion-guided biopsy using UroNavPinto and colleagues provide an overview of MRI/TRUS fusion-guided transperineal biopsy utilizing the UroNav platform.
Latest:
Focal therapy’s future in prostate cancer is bright, says Arvin George, MD"When we look at focal therapy in general, the better we're able to see, localize, identify and risk stratify prostate cancers, the better we're able to treat them and offer more personalized and focal treatments," says Arvin George, MD.
Latest:
UroView: Gallium 68 PSMA–Targeted PET Imaging in Prostate Cancer: Staging and OutcomesThis article features insights from Phillip Kuo, MD, PhD, and Andre Abreu, MD, on gallium 68 PSMA-targeted PET imaging in prostate cancer.
Latest:
New developments may change treatment of OAB"New treatments (pharmacological and device based) are currently in development to expand our OAB armamentarium," write Nathan Chertack, MD, and Gary Lemack, MD.
Latest:
New developments may change treatment of OAB"New treatments (pharmacological and device based) are currently in development to expand our OAB armamentarium," write Nathan Chertack, MD, and Gary Lemack, MD.
Latest:
Artificial intelligence is the new ghost author in urological research“Although the future of AI within science is uncertain, disclosure of the use of AI is an excellent first step to balance academic integrity with disruptive innovation,” the authors write.
Latest:
Acute-care urology during the pandemic: Lessons learned"The goal of this narrative is to share details and lessons learned during our on-call urology coverage in the midst of the current pandemic so we can help others by informing planning," write Alexander Small, MD, and Rich Matulewicz, MD.
Latest:
Active Surveillance in Muscle Invasive Bladder CancerTypes of patients with muscle invasive bladder cancer who may be candidates for a watch-and-wait approach.
Latest:
Addition to avelumab to best supportive care after firstline chemo improves OS in advanced urothelial CaAvelumab (Bavencio) as a maintenance treatment after chemotherapy significantly extended overall survival in patients with advanced urothelial cancer, according to findings from thephase III JAVELIN Bladder 100 trial.
Latest:
Management of UTUC using a kidney-sparing approachAdvances in endourology have made kidney-sparing treatments a viable treatment option.
Latest:
Jason Hafron, MD, on PSMA-PET in oligometastatic disease“Time will tell as we move forward, but it has allowed us to use MDT, with or without ADT and ARPIs, to potentially look at hormone-free treatments,” says Jason M. Hafron, MD, CMO.
Latest:
Robotics in GU oncology: Current status, future directionsThe breadth of applications will widen as the number of new platforms grows, according Joshua Calvert, MD, MPH.
